HVO vs. 4BB, FARN, AVCT, BVXP, FUM, SCLP, POLB, REDX, ETX, and OXB
Should you be buying hVIVO stock or one of its competitors? The main competitors of hVIVO include 4basebio (4BB), Faron Pharmaceuticals Oy (FARN), Avacta Group (AVCT), Bioventix (BVXP), Futura Medical (FUM), Scancell (SCLP), Poolbeg Pharma (POLB), Redx Pharma (REDX), e-therapeutics (ETX), and Oxford Biomedica (OXB). These companies are all part of the "biotechnology" industry.
4basebio (LON:4BB) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.
hVIVO has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.
hVIVO has a net margin of 27.47% compared to hVIVO's net margin of 0.00%. 4basebio's return on equity of 59.09% beat hVIVO's return on equity.
9.0% of 4basebio shares are owned by institutional investors. Comparatively, 14.2% of hVIVO shares are owned by institutional investors. 62.2% of 4basebio shares are owned by insiders. Comparatively, 39.2% of hVIVO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, hVIVO had 1 more articles in the media than 4basebio. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for 4basebio. hVIVO's average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.
hVIVO received 123 more outperform votes than 4basebio when rated by MarketBeat users.
4basebio has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, hVIVO has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.
Summary
hVIVO beats 4basebio on 10 of the 13 factors compared between the two stocks.
Get hVIVO News Delivered to You Automatically
Sign up to receive the latest news and ratings for HVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
